Effectiveness of lamivudine and interferon-α combination therapy versus interferon-α monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial
نویسندگان
چکیده
Corresponding author: Dr. Oguz Karabay, Department of Clinical Microbiology and Infectious Diseases, Izzet Baysal University School of Medicine, Golkoy, Bolu, Turkey. E-mail: [email protected] Hepatitis B infection is prevalent worldwide and a major health burden due to the associated complications of hepatic fibrosis, cirrhosis and hepatocellular carcinoma that occur in the context of chronic infection [1,2]. Immunization and greater public awareness have significantly decreased the incidence of new hepatitis B virus (HBV) infection, but the treatment of persons already infected remains an important international health concern [1-3]. In the Mediterranean basin, 3080% of patients with chronic hepatitis B are hepatitis B e antigen (HBeAg)-negative, in contrast to 10-40% rates in Northern European countries and the United States. HBeAg-negative chronic hepatitis B usually runs a Effectiveness of lamivudine and interferon-α combination therapy versus interferon-α monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial
منابع مشابه
Amantadine Plus Interferon-α Versus Interferon-α Monotherapy for the Treatment of Chronic Hepatitis-C Infection in β-Thalassemia Major Patients: A Randomized Double Blinded Pilot Study in Shiraz, Iran
Background: Hepatitis-C infection is a major problem in chronically transfused patients. We compared Interferon-α (INF-α) monotherapy with combination of INF-α and amantadine in the treatment of β-thalassemia major patients who were chronically infected with HCV.Materials and Methods: Forty six thalassemia major patients who were chronically infected with HCV were randomly divided into two grou...
متن کاملLamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
UNLABELLED BACKGROUND, AIM, AND METHODS: Alpha interferon is the generally approved therapy for HBe antigen positive patients with chronic hepatitis B, but its efficacy is limited. Lamivudine is a new oral nucleoside analogue which potently inhibits hepatitis B virus (HBV) DNA replication. To investigate the possibility of an additive effect of interferon-lamivudine combination therapy compared...
متن کاملinfection: a randomised trial treatment of patients with chronic hepatitis B Lamivudine and alpha interferon combination
Background, aim, and methods—Alpha interferon is the generally approved therapy for HBe antigen positive patients with chronic hepatitis B, but its eYcacy is limited. Lamivudine is a new oral nucleoside analogue which potently inhibits hepatitis B virus (HBV) DNA replication. To investigate the possibility of an additive eVect of interferon-lamivudine combination therapy compared with interfero...
متن کاملVitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)
α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...
متن کاملPeginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
BACKGROUND Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS A total of 814 patients with HBeAg-positive chron...
متن کامل